全球宏基因組學市場規模、份額和趨勢分析報告—產業概況和 2032 年預測

全球宏基因體學市場分析

在定序技術和生物資訊學進步的推動下，全球宏基因組學市場正在經歷顯著成長。宏基因體學是一門研究直接從環境樣本中提取的遺傳物質的學科，已成為了解微生物多樣性和生態系統功能的重要工具。定序成本的下降使得宏基因體學更容易取得，並被廣泛應用於環境監測、人類健康和農業等各個領域。增強的 DNA 分離方法和改進的篩選技術等技術創新進一步推動了市場的發展。此外，學術機構和公司開發綜合資料庫和支援大規模測序計畫的策略性舉措也促進了市場擴張。採用雲端運算進行資料管理以及直接面向消費者的基因檢測服務的出現也為宏基因組學市場帶來了新的機會。隨著該領域的不斷發展，宏基因組學有望在各個科學和工業領域發揮變革作用

全球宏基因體學市場規模

2024 年全球宏基因體學市場規模價值 24.1 億美元，預計到 2032 年將達到 42.4 億美元，2025 年至 2032 年預測期內的複合年增長率為 7.3%。除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察外，Data Bridge Market Research 策劃的市場報告還包括深度專家分析、患者流行病學、管道分析、定價分析和監管框架。

全球宏基因體學市場趨勢

 “宏基因組學定序創新的變革性影響”

Drop-Seq 等定序技術的創新極大地改變了宏基因體學領域。這些進步使得宏基因組學更加容易獲得且更具成本效益，使研究人員能夠以較低的成本分析許多細胞。特別是 Drop-Seq，它可以透過將單一細胞及其遺傳物質封裝在液滴中來實現高通量單細胞分析。該技術大大提高了研究複雜微生物群落的效率和精度，揭示了生態系統內複雜的關係和功能。同時分析大量細胞的能力加速了環境監測、臨床診斷和生物技術等各領域的發現。此外，定序成本的降低使得宏基因體學的應用更加民主化，使得小型研究機構和新創公司能夠為這個快速發展的領域做出貢獻。這些技術進步不僅擴大了宏基因體學研究的範圍，也開闢了新的創新和應用途徑，最終推動了全球宏基因體學市場的成長。

報告範圍和全球宏基因組學市場細分        

Global Metagenomics Market Definition

Metagenomics is a field of molecular biology that involves the comprehensive study of genetic material recovered directly from environmental samples. This approach allows scientists to analyze the collective genomes of microorganisms in a given environment, without the need for culturing individual species in a laboratory. By employing advanced sequencing technologies, metagenomics provides insights into the diversity, structure, and functions of microbial communities in various ecosystems, ranging from oceans and soils to the human gut. This holistic method helps identify previously unknown microorganisms, understand their metabolic capabilities, and elucidate their roles in natural processes and human health.

Global Metagenomics Market Dynamics

Drivers

• Rising Awareness of the Human Microbiome    

The growing awareness of the human microbiome's critical role in health and disease is significantly fueling the metagenomics market. Over the past decade, research has uncovered the profound impact that microbial communities residing in the human body, particularly in the gut, have on various aspects of health, including digestion, immunity, and metabolic processes. The microbiome is increasingly recognized for its influence on chronic conditions like autoimmune diseases, obesity, and even mental health disorders, which has sparked interest in understanding its complexities. As scientists delve deeper into the diversity of microbial species and their interactions, metagenomic analysis has become an essential tool for uncovering microbial imbalances and their associations with disease. This heightened interest is driving the demand for advanced metagenomics technologies that can analyze large-scale genomic data of these microbial communities. Researchers and healthcare professionals are using metagenomics to explore new therapeutic approaches, such as microbiome-based treatments and personalized medicine, offering hope for more targeted and effective therapies. The growing body of knowledge about the microbiome's role in health and disease is not only expanding research opportunities but also creating new avenues for diagnostics, prevention, and treatment, thereby accelerating the adoption of metagenomic analysis in both clinical and research settings.

• Increased Focus on Precision Medicine  

Metagenomics is becoming a cornerstone of precision medicine, offering invaluable insights into the genetic composition of microbiomes and their influence on individual health. By analyzing the diversity and functions of microbial communities within the body, metagenomic techniques enable the identification of unique microbial signatures associated with specific diseases. This understanding is crucial for developing personalized treatment plans tailored to an individual's unique microbiome, thereby enhancing therapeutic efficacy. For conditions such as gastrointestinal disorders, autoimmune diseases, and even cancer, where the microbiome plays a critical role in disease progression, metagenomics allows for the identification of microbial imbalances that may influence the course of the disease. The ability to tailor therapies based on an individual's microbiome composition opens up new possibilities for more effective, targeted treatments that go beyond traditional one-size-fits-all approaches. In addition, metagenomics aids in monitoring disease progression and response to treatment, helping healthcare providers adjust therapies in real time. As the demand for personalized healthcare continues to grow, the role of metagenomics in precision medicine becomes more pivotal, driving both the development of new diagnostic tools and the creation of microbiome-based therapies, further accelerating the market's expansion.

Opportunities

• Increasing Automation and Integration of Artificial Intelligence (AI)      

人工智慧 (AI)、機器學習和自動化與宏基因組學的整合正在顯著改變數據分析，提高速度和準確性。宏基因組數據龐大且複雜，傳統的手動分析既耗時又容易出錯。人工智慧和機器學習演算法有助於快速處理大型資料集，識別可能被忽略的模式和相關性。這些技術還可以自動執行序列比對、分類學分類和功能註釋等重複性任務，從而簡化工作流程並減少人為錯誤。因此，宏基因組分析變得更加容易獲得、高效和具有成本效益，這對醫療保健、農業和環境監測等更廣泛的行業具有吸引力。在醫療保健領域，人工智慧增強型宏基因組學能夠更快地識別病原體、微生物群落和疾病生物標記物，支援更快的診斷和治療。同樣，在農業領域，人工智慧可以優化基於微生物的土壤健康和害蟲管理解決方案。這些過程的自動化也減少了對專業知識的需求，使得非專家也能進行宏基因體分析。隨著人工智慧的不斷發展，其與宏基因體學的融合不僅會增強現有的能力，還會創造新的創新機會，進一步推動各領域對宏基因組學工具的應用，加速市場成長。

•  以微生物組為基礎的疾病治療           

基於微生物組的治療方法的出現為現代醫學帶來了重大機遇，而宏基因組學在釋放這一潛力方面發揮著至關重要的作用。人們正在探索基於微生物組的療法，包括益生菌、益生元和糞便微生物群移植 (FMT)，以治療各種疾病，從胃腸道疾病到代謝疾病甚至神經系統疾病。宏基因組學可以識別特定的微生物菌株及其功能，從而了解這些微生物如何影響健康和疾病。透過分析微生物群落的基因組成，研究人員可以精確地找到能夠恢復微生物群平衡並緩解各種疾病症狀的有益微生物。例如，益生菌利用有益細菌重新填充腸道，而益生元則滋養這些有益微生物以支持它們的生長。糞便微生物移植 (FMT) 涉及將健康的糞便樣本從捐贈者轉移到患者體內，以恢復腸道內的微生物平衡。隨著我們對微生物組的了解不斷加深，宏基因組學使得開發針對個人獨特微生物組特徵的個人化療法成為可能。這種方法有望徹底改變醫學，提供有針對性的、更有效的治療方法，最大限度地減少副作用，並以以前不可能的方式推進個人化護理。

限制/挑戰

• 定序和設備成本高昂  

雖然定序技術的進步已顯著降低了每個基因組定序的成本，但對下一代定序儀等宏基因組學設備的初始投資仍然很高。這些最先進的儀器對於大規模宏基因組學研究至關重要，但價格卻非常昂貴，特別是對於預算有限的小型研究機構或醫療機構。除了設備成本外，還有與數據分析和解釋所需的試劑、消耗品和生物資訊軟體相關的大量費用。由於宏基因組資料集龐大且需要安全的長期儲存解決方案，資料儲存和管理基礎架構的成本進一步增加了財務負擔。對於許多機構，特別是發展中地區的機構來說，這些高昂的成本造成了巨大的進入壁壘，限制了他們獲得尖端宏基因組學技術的機會。這種資金壓力限制了宏基因組學在臨床環境中的應用，而其改善診斷和治療計劃的潛力可能會帶來顯著的益處。因此，儘管宏基因組學的前景越來越廣闊，但這些成本對於更廣泛的全球實施（特別是在資源受限的環境中）提出了挑戰，並可能減緩該領域的創新和研究步伐。

• 數據分析的複雜性

宏基因組學市場面臨的關鍵挑戰之一是數據分析的固有複雜性。宏基因組資料集通常包含來自不同微生物群落的大量遺傳訊息，因此難以準確分析和解釋資料。這些資料集可能包含數千甚至數百萬種微生物物種，每種物種都有獨特的遺傳特徵，增加了複雜性。分析如此大規模的數據需要先進的生物資訊工具和專門的演算法來處理微生物基因組的複雜性。此外，處理和儲存這些大型資料集需要強大的運算能力，這對於資源有限的小型研究機構或組織來說可能是一個重大障礙。由於需要微生物學和計算生物學的專家級知識來準確解釋結果，因此複雜性進一步加劇。這種專業知識通常很稀缺，缺乏熟練的人員會阻礙宏基因組學技術的有效使用。因此，數據分析的複雜性限制了宏基因組學的可及性和廣泛採用，尤其是在臨床和小規模研究環境中。由於缺乏使用者友善的工具和簡化的數據解釋流程，許多組織難以充分發揮宏基因組學的潛力。

本市場報告提供了最新發展、貿易法規、進出口分析、生產分析、價值鏈優化、市場份額、國內和本地化市場參與者的影響的詳細信息，分析了新興收入領域的機會、市場法規的變化、戰略市場增長分析、市場規模、類別市場增長、應用領域和主導地位、產品批准、產品發布、地理擴展、市場技術創新。要獲取更多市場信息，請聯繫 Data Bridge Market Research 獲取分析師簡報，我們的團隊將幫助您做出明智的市場決策，實現市場成長。

全球宏基因組學市場範圍

市場根據產品和服務、工作流程、技術和應用進行細分。這些細分市場之間的成長將幫助您分析行業中成長微弱的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。

產品和服務  

• 試劑和耗材
• 儀器
• 服務
•  分析和數據解釋解決方案

按工作流程

• 樣品處理和文庫製備
• 定序
• 數據處理與分析 

科技

• 散彈槍宏基因組定序
• 16S rRNA測序
•  宏轉錄組學
• 全基因組定序與從頭組裝

 應用

• 藥物研發
• 臨床診斷
• 土壤微生物組應用
•  工業應用
• 生態與環境應用
• 獸醫應用
• 其他應用

全球宏基因體學市場分析

對市場進行分析，並按國家、產品和服務、工作流程、技術和應用提供市場規模洞察和趨勢，如上所述。

市場報告涉及的國家有：北美的美國、加拿大、墨西哥、德國、瑞典、波蘭、丹麥、義大利、英國、法國、西班牙、荷蘭、比利時、瑞士、土耳其、俄羅斯、歐洲的其他地區、日本、中國、印度、韓國、紐西蘭、越南、澳洲、新加坡、馬來西亞、泰國、印尼、菲律賓、亞太地區（APAC）的其他地區、巴西、阿根廷、南美洲的其他地區、歐洲地區（AME、AME）。

由於主要生命科學公司的存在和技術進步，北美預計將主導市場。美國和加拿大是推動這一主導地位的主要市場。研發方面的投資為宏基因體學培育了強大的基礎設施，推動了該領域的創新和成長。此外，學術機構和產業參與者之間的合作進一步加強了市場。這種支持性環境使北美繼續處於宏基因組學進步和市場擴張的前沿。

Asia Pacific is expected to be fastest growing region in the market due to presence of countries like China and India are making substantial investments in genomic research, fueling significant market expansion. These investments are enhancing research capabilities, infrastructure, and technological advancements in the region. The increasing focus on personalized medicine, disease diagnosis, and agricultural applications is driving demand for metagenomic solutions. With supportive government policies and growing academic-industry collaborations, the Asia-Pacific region is set to become a key player in the global metagenomics market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Global Metagenomics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Global Metagenomics Market Operating in the Market Are:

• Agilent Technologies, Inc (U.S.)
• ENTEROME (France)
• IntegraGen (France)
• Oxford Nanopore Technologies (U.K.)
• QIAGEN (Germany)
• Illumina, Inc (U.S.)
• Pacific Biosciences of California, Inc (U.S.)
• Swift Biosciences Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• BGI (China)
• Bio-Rad Laboratories, Inc. (U.S.)
• Promega Corporation (U.S.)

Latest Developments in Global Metagenomics Market

• In January 2024, Eurofins Genomics inaugurated a certified sequencing lab in Bothell, Washington. This facility leverages the Oxford Nanopore platform to deliver rapid results within 12 hours. The lab has partnered with 30 Seattle-based labs to enhance its service reach and efficiency
• In February 2024, MGI Tech Co., Ltd. entered into a partnership with MetaGenoPolis, a unit within France's National Research Institute for Agriculture, Food and the Environment (INRAE). This collaboration followed MetaGenoPolis' selection as a core lab for the Million Microbiomes from Humans Project (MMHP). The partnership aims to advance metagenomics research by leveraging MGI's ultra-high throughput DNBSEQ-T7 sequencer to process samples from the project "Le French Gut" and other MMHP-related research
• In June 2023, Eurofins Genomics U.S. launched an express Oxford Nanopore sequencing service that offers same-day results2. This service leverages Gen3 NGS (next-generation sequencing) technology to provide a low-cost, whole plasmid sequencing solution with single-base accuracy of up to 99%2. The service aims to bridge the gap between Sanger and NGS by offering an affordable and fast solution for long-read sequencing
• In March 2023, Macrogen Inc. became the first company to introduce the NovaSeq X Plus system to Korea, marking its entry into the Asian market. This high-precision, whole-genome sequencing system, developed by Illumina, significantly boosts Macrogen's sequencing capacity and supports its genome foundry business. The installation of the NovaSeq X Plus at Macrogen's Genome Center in Korea was followed by plans to install additional units across its global affiliates, including in Japan and Europe

SKU-50324